The goals of treatment are to decrease the frequency of angina, increase longevity, and improve patients' QOL. Management of risk factors is an essential component of this therapy. Also important ...

The diagnosed prevalent cases of angina pectoris is expected to increase from 19.58 million cases in 2018 to 22.79 million cases in 2028, at an annual growth rate (AGR) of 1.64% across the seven ...

In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug ...

The ASSOCIATE study investigators have reported that the I f current inhibitor, ivabradine, is safe, improves exercise performance, and delays the development of ischemia in patients with chronic ...

For informational purposes only. Consult a medical professional for advice. Source: Focus Medica Angina, also known as angina pectoris, is chest pain or pressure, a symptom of coronary heart disease, ...

Cardiovascular diseases including myocardial infarction (MI), angina pectoris, stroke, heart failure (HF) and atrial ...

Researchers have discovered that the smooth muscle cells that line the arteries of people with atherosclerosis can change ...

Individuals should have at least 7 to 8 hours of sleep to maintain optimal health and wellness. Sleep deprivation reduces ...

To reduce combined risk of death and nonfatal MI after MI or unstable angina pectoris. To reduce combined risk of MI and sudden death in chronic stable angina. Revascularization procedures.

Nicotine 7mg/24hr, 14mg/24hr, 21mg/24hr; transdermal patch (clear or original color). Avoid immediately post-MI, in arrhythmias, or severe or worsening angina pectoris. Uncontrolled hypertension.